Journal Reviews

BJUI International journal cover image.

BCG after TURBT – does timing matter?

2 March 2022 | | Urologic Oncology | #BladderCancer, #blcsm, #uroonc, BCG-unresponsive, bacille Calmette-Guérin, bladder cancer, intravesical therapy, transurethral resection of bladder tumour

Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...

Comparing intravesical chemohyperthermia with Mitomycin C versus BCG in treating bladder cancer

1 July 2016 | | Urologic Oncology | BCG, Device-assisted therapy, Hyperthermia, Intravesical chemotherapy, Mitomycin-C, Non–muscle-invasive bladder cancer, Radiofrequency, Randomised controlled trial, Recurrence rate, Thermochemotherapy

In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

1 March 2015 | | Urologic Oncology | Animal, BCG Connaught, BCG Tice, BCG vaccine, Flow cytometry, Immunotherapy, Intravesical drug administration, Models, Randomized controlled trial, Urinary bladder neoplasms

Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...